Royalty Pharma plc
RPRX
$31.28
$0.110.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.26B | 2.27B | 2.24B | 2.24B | 2.35B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.26B | 2.27B | 2.24B | 2.24B | 2.35B |
| Cost of Revenue | 732.46M | 491.91M | 996.65M | 1.03B | 560.66M |
| Gross Profit | 1.53B | 1.77B | 1.24B | 1.21B | 1.79B |
| SG&A Expenses | 236.67M | 228.27M | 228.78M | 221.71M | 249.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 971.13M | 722.18M | 1.28B | 1.30B | 862.40M |
| Operating Income | 1.29B | 1.54B | 960.19M | 939.40M | 1.49B |
| Income Before Tax | 1.33B | 1.71B | 1.03B | 1.19B | 1.70B |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.33K | 1.71K | 1.03K | 1.19K | 1.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -471.83M | -568.94M | -356.53M | -387.87M | -565.25M |
| Net Income | 858.98M | 1.15B | 673.24M | 798.86M | 1.13B |
| EBIT | 1.29B | 1.54B | 960.19M | 939.40M | 1.49B |
| EBITDA | -- | 614.31M | 767.17M | 1.02B | 1.50B |
| EPS Basic | 1.81 | 2.56 | 1.51 | 1.79 | 2.54 |
| Normalized Basic EPS | 0.49 | 0.64 | 0.29 | 0.20 | 0.67 |
| EPS Diluted | 1.80 | 2.56 | 1.50 | 1.78 | 2.54 |
| Normalized Diluted EPS | 0.40 | 0.48 | 0.22 | 0.15 | 0.50 |
| Average Basic Shares Outstanding | 1.94B | 1.79B | 1.79B | 1.79B | 1.79B |
| Average Diluted Shares Outstanding | 2.38B | 2.38B | 2.39B | 2.40B | 2.41B |
| Dividend Per Share | 0.84 | 0.83 | 0.82 | 0.81 | 0.80 |
| Payout Ratio | 43.83% | 32.50% | 54.64% | 45.50% | 31.58% |
